ArticleRMD open2015

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study.

Michael Schiff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.